Pharma Focus Asia

Almac Group Invests US$540 million (£400mn) to Expand Production Capacity in Ireland

Introduction:

Almac Group invests US$540 million (£400mn) for the completion of two new purpose-built facilities at Ireland. 

Features: 

The primary project among these two major endeavours involves the construction of a 32,000 square feet custom-built facility. 

This facility is specifically designed for high-volume operations and will significantly amplify capacity for commercial manufacturing and packaging of sachet drug product presentations. 

The investment involves the addition of more large-scale manufacturing suites, the implementation of automated primary and secondary sachet packaging technologies, and an expansion of the QC laboratory testing capacity. 

The second project involves the development of a 28,000 square feet GMP facility. This facility not only doubles the peptide API manufacturing capacity but also enhances synthesis, purification, and isolation capabilities.

It is specifically designed to meet the demand for both clinical development and commercial products.

This expansion enables to provide comprehensive support throughout every stage of a drug’s lifecycle, from early development through to commercialisation.

The new peptide API manufacturing facility will substantially bolster broader development and manufacturing expansion initiatives.

Specifications:

Name         Almac Group
Type          Expansion
Budget     US$540 million (£400mn)

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference